{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:27:44Z","timestamp":1758040064549,"version":"3.44.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.amjcard.2014.05.028","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T05:33:49Z","timestamp":1402032829000},"page":"528-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Usefulness of Postmarket Studies to Evaluate Long-Term Safety of Coronary Eluting Stents (from the ENDEAVOR and PROTECT Programs)"],"prefix":"10.1016","volume":"114","clinical-trial-number":[{"clinical-trial-number":"nct00314275","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Moshe","family":"Vardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremiah","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula J.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald E.","family":"Cutlip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2014.05.028_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.ackd.2011.09.004","article-title":"Observational studies versus randomized controlled trials: avenues to causal inference in nephrology","volume":"19","author":"Kovesdy","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.amjcard.2014.05.028_bib2","first-page":"MR000012","article-title":"Randomisation to protect against selection bias in healthcare trials","author":"Kunz","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjcard.2014.05.028_bib3","doi-asserted-by":"crossref","first-page":"56M","DOI":"10.1016\/j.amjcard.2007.08.023","article-title":"Four-year clinical follow-up after implantation of the Endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study","volume":"100","author":"Meredith","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2014.05.028_bib4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.105.591206","article-title":"Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial","volume":"114","author":"Fajadet","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2014.05.028_bib5","first-page":"76","article-title":"Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry","volume":"3","author":"Schultheiss","year":"2007","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2014.05.028_bib6","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.jacc.2006.08.035","article-title":"Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial","volume":"48","author":"Kandzari","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2014.05.028_bib7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jacc.2009.08.067","article-title":"A\u00a0randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial","volume":"9","author":"Leon","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2014.05.028_bib8","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(12)61336-1","article-title":"Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial","volume":"380","author":"Camenzind","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2014.05.028_bib9","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2014.05.028_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.amjcard.2014.05.028_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jacc.2006.02.060","article-title":"Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial","volume":"48","author":"Pinto","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2014.05.028_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcin.2010.01.010","article-title":"The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of \u201coculostenotic\u201d reintervention in patients with intermediate lesions","volume":"3","author":"Uchida","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2014.05.028_bib13","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/cncr.21907","article-title":"Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants","volume":"106","author":"Elting","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.amjcard.2014.05.028_bib14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/archinternmed.2007.56","article-title":"Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions","volume":"168","author":"Dhruva","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2014.05.028_bib15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jama.1992.03490110055029","article-title":"The exclusion of the elderly and women from clinical trials in acute myocardial infarction","volume":"268","author":"Gurwitz","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2014.05.028_bib16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.286.6.708","article-title":"Representation of elderly persons and women in published randomized trials of acute coronary syndromes","volume":"286","author":"Lee","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2014.05.028_bib17","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.110.991075","article-title":"Do postmarketing surveillance studies represent real-world populations? Clinical perspective","volume":"123","author":"Yeh","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2014.05.028_bib18","first-page":"327","article-title":"Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task Force","volume":"69","author":"Hodgson","year":"2007","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2014.05.028_bib19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMp1114695","article-title":"Here we go again\u2014failure of postmarketing device surveillance","volume":"366","author":"Hauser","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2014.05.028_bib20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMp1114865","article-title":"Postmarketing surveillance of medical devices\u2014filling in the gaps","volume":"366","author":"Resnic","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2014.05.028_bib21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMp1109094","article-title":"Medical devices\u2014balancing regulation and innovation","volume":"365","author":"Curfman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2014.05.028_bib22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMp1109150","article-title":"Medical devices and health\u2014creating a new regulatory framework for moderate-risk devices","volume":"365","author":"Challoner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2014.05.028_bib23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMhle1113918","article-title":"Regulation of medical devices in the United States and European Union","volume":"366","author":"Kramer","year":"2012","journal-title":"N\u00a0Engl J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914914012211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914914012211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:26:56Z","timestamp":1757572016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914914012211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0002914914012211"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2014.05.028","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of Postmarket Studies to Evaluate Long-Term Safety of Coronary Eluting Stents (from the ENDEAVOR and PROTECT Programs)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2014.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}